See more : Kudelski SA (0QNQ.L) Income Statement Analysis – Financial Results
Complete financial analysis of PetVivo Holdings, Inc. (PETV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PetVivo Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- The Victoria Mills Limited (VICTMILL.BO) Income Statement Analysis – Financial Results
- SLC Agrícola S.A. (SLCJF) Income Statement Analysis – Financial Results
- HJ Magnolia Yongpyong Hotel & Resort (070960.KS) Income Statement Analysis – Financial Results
- Hall of Fame Village, LLC (HOFVW) Income Statement Analysis – Financial Results
- GigCapital5, Inc. (GIA-UN) Income Statement Analysis – Financial Results
PetVivo Holdings, Inc. (PETV)
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 968.71K | 917.16K | 115.59K | 12.58K | 3.59K | 77.94K | 1.51K | 7.12K | 75.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 229.18K | 526.82K | 201.15K | 10.70K | 19.71K | 77.94K | 643.39K | 746.85K | 743.63K | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 739.53K | 390.35K | -85.57K | 1.88K | -16.12K | 0.00 | -641.88K | -739.72K | -668.63K | -1.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 76.34% | 42.56% | -74.03% | 14.97% | -449.33% | 0.00% | -42,508.48% | -10,383.51% | -891.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.27M | 690.58K | 474.88K | 98.23K | 12.67K | 200.98K | 118.94K | 167.89K | 168.60K | 4.40K | 119.30K | 0.00 | 0.00 | 157.30K |
| General & Administrative | 6.69M | 5.02M | 3.15M | 1.77M | 1.23M | 3.60M | 2.17M | 16.23M | 3.16M | 1.20M | 36.85M | 82.40K | 102.40K | 103.68K |
| Selling & Marketing | 3.40M | 3.41M | 1.35M | 94.98K | 171.51K | 38.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.80K |
| SG&A | 10.09M | 8.43M | 4.50M | 1.86M | 1.40M | 3.64M | 2.17M | 16.23M | 3.16M | 1.20M | 36.85M | 82.40K | 102.40K | 105.48K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 559.54K | 646.92K | 2.17M | 16.23M | 3.16M | 0.00 | 24.44M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.36M | 9.12M | 4.97M | 1.96M | 1.97M | 4.49M | 2.29M | 16.40M | 3.33M | 1.20M | 36.97M | 82.40K | 102.40K | 262.78K |
| Cost & Expenses | 11.59M | 9.65M | 5.17M | 1.97M | 1.99M | 4.57M | 2.29M | 16.40M | 3.33M | 1.20M | 36.97M | 82.40K | 102.40K | 262.78K |
| Interest Income | 0.00 | 15.84K | 9.85K | 228.60K | 32.19K | 84.95K | 0.00 | 0.00 | 0.00 | 0.00 | 19.53K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 228.60K | 32.19K | 84.95K | 74.02K | 188.51K | 270.58K | 399.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 126.85K | 114.43K | 65.15K | 86.71K | 559.54K | 646.92K | 643.39K | 746.85K | 743.63K | 10.48K | 36.97M | 3.81K | 227.00 | 659.00 |
| EBITDA | -10.49M | -8.62M | -4.99M | -1.87M | -1.49M | -3.92M | -1.64M | -16.39M | -2.51M | -1.20M | -19.68K | -78.59K | -102.18K | -262.12K |
| EBITDA Ratio | -1,083.35% | -952.23% | -4,345.73% | -14,885.32% | -39,724.53% | -5,032.45% | -108,737.02% | -219,579.00% | -3,343.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.62M | -8.73M | -5.06M | -1.96M | -2.02M | -4.67M | -2.29M | -16.39M | -3.25M | -1.20M | -36.97M | -82.40K | -102.40K | -262.78K |
| Operating Income Ratio | -1,096.45% | -952.23% | -4,374.69% | -15,574.72% | -56,190.97% | -5,995.70% | -151,345.50% | -230,062.51% | -4,334.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -333.96K | 15.84K | 41.53K | -1.56M | -66.60K | -84.95K | -52.02K | -132.05K | -1.48M | -363.84K | -19.68K | -3.81K | -227.00 | -659.00 |
| Income Before Tax | -10.96M | -8.72M | -5.01M | -3.52M | -2.08M | -4.76M | -2.34M | -16.52M | -4.73M | -1.57M | -36.99M | -86.21K | -102.63K | -263.44K |
| Income Before Tax Ratio | -1,130.92% | -950.50% | -4,338.76% | -28,007.47% | -58,047.21% | -6,104.70% | -154,790.60% | -231,916.03% | -6,307.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.84K | -73.21K | 228.60K | 32.19K | 84.95K | 74.02K | -990.17K | -1.08M | 388.68K | -19.68K | 0.00 | 0.00 | 0.00 |
| Net Income | -10.96M | -8.70M | -4.94M | -3.75M | -2.11M | -4.76M | -2.34M | -15.53M | -3.65M | -1.57M | -36.99M | -86.21K | -102.63K | -263.44K |
| Net Income Ratio | -1,130.92% | -948.77% | -4,275.42% | -29,824.89% | -58,944.23% | -6,104.70% | -154,790.60% | -218,017.03% | -4,868.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.78 | -0.85 | -0.56 | -0.61 | -0.10 | -1.03 | -0.61 | -7.71 | -2.07 | -0.91 | -308.77 | -1.55 | -2.00 | -5.86 |
| EPS Diluted | -0.78 | -0.85 | -0.56 | -0.61 | -0.10 | -1.03 | -0.61 | -7.71 | -2.07 | -0.91 | -308.77 | -1.55 | -2.00 | -5.86 |
| Weighted Avg Shares Out | 13.97M | 10.22M | 8.76M | 6.20M | 21.22M | 4.61M | 3.81M | 2.01M | 1.77M | 1.71M | 119.81K | 55.69K | 51.37K | 44.98K |
| Weighted Avg Shares Out (Dil) | 13.97M | 10.22M | 8.76M | 6.20M | 21.22M | 4.61M | 3.81M | 2.01M | 1.77M | 1.71M | 119.81K | 55.69K | 51.37K | 44.98K |
PetVivo Holdings, Inc. (PETV) Q3 2023 Earnings Call Transcript
PetVivo Holdings, Inc. (NASDAQ:PETV ) Q3 2023 Earnings Conference Call February 9, 2023 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - President and CEO Bob Folkes - CFO Conference Call...
PetVivo Holdings, Inc. to Present at Sequire Virtual Small Cap Conference on December 8th, 2022
MINNEAPOLIS, MN, Dec. 05, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today hat it will...
PetVivo Holdings, Inc. (PETV) Q2 2023 Earnings Call Transcript
PetVivo Holdings, Inc. (NASDAQ:PETV ) Q2 2023 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants John Dolan – Chief Business Development Officer and General Counsel John Lai – President and Chief Executive Officer Bob Folkes – Chief...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR SECOND QUARTER ENDED September 30, 2022
MINNEAPOLIS, MN, US, Nov. 03, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 10, 2022...
PETVIVO HOLDINGS, INC. ANNOUNCES PARTICIPATION AT THE H.C.
MINNEAPOLIS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for pets, is pleased to announce it will be...
PetVivo Holdings, Inc. (PETV) CEO John Lai on Q1 2023 Results - Earnings Call Transcript
PetVivo Holdings, Inc. (NASDAQ:PETV ) Q1 2023 Results Conference Call August 11, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief...
PetVivo Holdings Is A Growth Stock Worth a Look
The market conditions aren't screaming “buy growth stocks now” at us but that doesn't mean all growth stocks, like PetVivo (OTCMKTS: PETV), are or will suffer the same afflictions. PetVivo caught our attention because of two things; its market and...
PetVivo Holdings, Inc. (PETV) CEO John Lai on Q4 2022 Results - Earnings Call Transcript
PetVivo Holdings, Inc. (NASDAQ:PETV ) Q4 2022 Results Conference Call June 29, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief...
PetVivo Holdings, Inc. (PETV) CEO John Lai on Q3 2022 Results - Earnings Call Transcript
PetVivo Holdings, Inc. (PETV) CEO John Lai on Q3 2022 Results - Earnings Call Transcript
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THIRD QUARTER ENDED DECEMBER 31, 2021 [UPDATED]
MINNEAPOLIS, MN, US, Feb. 03, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, February 10, 2022...
Source: https://incomestatements.info
Category: Stock Reports